

Curriculum Vitae

Personal information **Marianne Delville**

Work experience

2021-2024 Translational research director at One Biosciences, Paris

- Clinical research direction: selection of area of interest, clinical study design, scientific discussion with KOL, set-up of clinical projects from design, regulatory writing and submission and operational roadmap and follow-up. Opening of 4 studies from collaborations to full sponsorship
- Steering translational program research, management of a research team of three engineers and budget planification
- Analysis of single cell data and translational validation of new therapeutics targets

2019-2021 Associate Professor in Clinical Immunology, Biotherapy and Apheresis department, currently in detachment Necker Hospital, AP-HP, and Paris Cité University

- Patients' follow-up in day care (9 beds) and intensive care unit for plasmapheresis
- Team management
- Clinical research from preclinical development, study design, writing of regulatory document including IMPD, investigator brochure and protocol, patient inclusion
- Teaching and training of two master's degree students

2016-2019 PhD thesis, INSERM grant
Human Lympho-Hematopoiesis Laboratory Imagine Institute, and Paris Cité University

- Pre-clinical development of a new gene therapy strategy
- Writing of publications and grant applications

2014-2016 Fellow, Biotherapy and Apheresis department, Necker, APHP
2012-2014 Fellow, Nephrology and Renal Transplantation, Necker, APHP
2010-2011 Visiting Scholar, Sarwal's lab, Stanford University, CA, USA

Education and training

2024 University graduation Medical affairs
Feb. 2020 Good Clinical Practice accreditation
Nov. 2019 PhD, Cell and molecular biology, Université de Paris
Feb. 2018 Animal experimentation accreditation, project leader
June 2014 Biostatistics CESAM, specialized in Clinical Research
Sept 2012 Medical doctor, Nephrology, with honors
June 2011 Master degree, Fundamental immunology, Paris 6 University, ENS Ulm and Pasteur Institute, with honors
June 2001 Ecole Normale Supérieure, ENS Ulm, Paris

Additional information

Publications

1. Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction.

Lamarthée B, Marchal A, Charbonnier S, Blein T, Leon J, Martin E, Rabaux L, Vogt K, Titeux M, **Delville M**, Vinçon H, Six E, Pallet N, Michonneau D, Anglicheau D, Legendre C, Taupin JL, Nemazany I, Sawitzki B, Latour S, Cavazzana M, André I, Zuber J.

Nat Commun. 2021 Nov; PMID: 34750385

2. Therapeutic plasma exchange for life-threatening pediatric disorders.

Diana JS, Manceau S, Rabeony T, Elie C, Jolaine V, Zamora S, Aubart M, Salvi N, Bodemer C, Bader-Meunier B, Barnérias C, Iserin F, Chardot C, Lacaille F, Renolleau S, Salomon R, Joseph L, Cavazzana M, Lefrere F, Dupic L, **Delville M**.

J Clin Apher. 2021 Dec. ; PMID: 34469617

3. Single-cell analysis of FOXP3 deficiencies in humans and mice unmasks intrinsic and extrinsic CD4+ T cell perturbations.

Zemmour D, Charbonnier LM, Leon J, Six E, Keles S, **Delville M**, Benamar M, Baris S, Zuber J, Chen K, Neven B, Garcia-Lloret MI, Ruemmele FM, Brugnara C, Cerf-Bensussan N, Rieux-Laucat F, Cavazzana M, André I, Chatila TA, Mathis D, Benoist C.

Nat Immunol. 2021 May; PMID: 33833438

4. A combination of cyclophosphamide and interleukin-2 allows CD4+ T cells converted to Tregs to control scurfy syndrome.

Delville M, Bellier F, Leon J, Klifa R, Lizot S, Vinçon H, Sobrino S, Thouenon R, Marchal A, Garrigue A, Olivré J, Charbonnier S, Lagresle-Peyrou C, Amendola M, Schambach A, Gross D, Lamarthée B, Benoist C, Zuber J, André I, Cavazzana M, Six E.

Blood. 2021 Apr; PMID: 33545713

5. Vascular access for optimal hematopoietic stem cell collection.

Couzin C, Manceau S, Diana JS, Joseph L, Magnani A, Magrin E, Amrane H, Dupont E, Raphalen JH, Sibon D, Marçais A, Suarez F, Cavazzana M, Lefrère F, **Delville M**.

J Clin Apher. 2021 Feb; PMID: 32854142

6. Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs.

Six E, Guilloux A, Denis A, Lecoules A, Magnani A, Vilette R, Male F, Cagnard N, **Delville M**, Magrin E, Caccavelli L, Roudaut C, Plantier C, Sobrino S, Gregg J, Nobles CL, Everett JK, Hacein-Bey-Abina S, Galy A, Fischer A, Thrasher AJ, André I, Cavazzana M, Bushman FD.

Blood. 2020 Apr; PMID: 32040546

7. Renal transplantation: Procedure and early follow-up.

Anglicheau D, Tinel C, Canaud G, Loupy A, Zuber J, **Delville M**, Rabaté C, Scemla A, Snanoudj R, Sberro-Soussan R, Mamzer-Bruneel MF, Bererhi L, Martinez F, Timsit MO, Rabant M, Correas JM, Bienaimé F, Duong JP, Hélénon O, Prié D, Méjean A, Legendre C.

Nephrol Ther. 2019 Nov; PMID: 31640943

8. Genomic Mismatch at LIMS1 Locus and Kidney Allograft Rejection.

Lamarthée B, **Delville M**, Anglicheau D.

N Engl J Med. 2019 Aug 29;381(9):e16. doi: 10.1056/NEJMc1908072.

PMID: 31461604 No abstract available. Sensitization to endothelial cell antigens: Unraveling the cause or effect paradox. Jackson AM, **Delville M**, Lamarthée B, Anglicheau D. Hum Immunol. 2019 May; PMID: 31461604

9. Sensitization to endothelial cell antigens: Unraveling the cause or effect paradox.

Jackson AM, **Delville M**, Lamarthée B, Anglicheau D.

Hum Immunol. 2019 Aug; PMID: 31054781

10. Non anti-HLA antibodies and acute rejection: A critical viewpoint

Anglicheau D, **Delville M**, Lamarthee B.

Nephrol Ther. 2019 Apr; PMID: 30981396

11. Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma.

Delville M, Touzot F, Couzin C, Hmitou I, Djerroudi L, Ouedrani A, Lefrère F, Tuchman-Durand C, Mollet C, Fabreguettes JR, Ferry N, Laganier L, Magnani A, Magrin E, Jolaine V, Saez-Cirion A, Wolstein O, Symonds G, Frange P, Moins-Teisserenc H, Chaix-Baudier ML, Toubert A, Larghero J, Parquet N, Brignier AC, Barré-Sinoussi F, Oksenhendler E, Cavazzana M.

Mol Ther Methods Clin Dev. 2019 Feb; PMID: 30911587

12. Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens.

Delville M, Lamarthée B, Pagie S, See SB, Rabant M, Burger C, Gatault P, Giral M, Thauinat O, Arzouk N, Hertig A, Hazzan M, Matignon M, Mariat C, Caillard S, Kamar N, Sayegh J, Westeel PF, Garrouste C, Ladrière M, Vuiblet V, Rivalan J, Merville P, Bertrand D, Le Moine A, Duong Van Huyen JP, Cesbron A, Cagnard N, Alibeu O, Satchell SC, Legendre C, Zorn E, Taupin JL, Charreau B, Anglicheau D.

J Am Soc Nephrol. 2019 Apr; PMID: 30850439

13. A Nontoxic Transduction Enhancer Enables Highly Efficient Lentiviral Transduction of Primary Murine T Cells and Hematopoietic Stem Cells.

Delville M, Soheili T, Bellier F, Durand A, Denis A, Lagresle-Peyrou C, Cavazzana M, Andre-Schmutz I, Six E.

Mol Ther Methods Clin Dev. 2018 Aug; PMID: 30191160

14. FSGS ACTH Gel: Part of the Answer?

Delville M, Canaud G, Legendre C.

Transplantation. 2019 Jan; PMID: 29894412

15. Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: A retrospective survey by

the international sickle cell disease observatory.

Ribeil JA, Labopin M, Stanislas A, Deloison B, Lemerrier D, Habibi A, Albinni S, Charlier C, Lortholary O, Lefrere F, De Montalembert M, Blanche S, Galactéros F, Tréluyer JM, Gluckman E, Ville Y, Joseph L, **Delville M**, Benachi A, Cavazzana M.

Am J Hematol. 2018 Jun; PMID: 29603363

16. Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion.

Lagresle-Peyrou C, Lefrère F, Magrin E, Ribeil JA, Romano O, Weber L, Magnani A, Sadek H, Plantier C, Gabrion A, Ternaux B, Félix T, Couzin C, Stanislas A, Tréluyer JM, Lamhaut L, Joseph L, **Delville M**, Miccio A, André-Schmutz I, Cavazzana M.

Haematologica. 2018 May; PMID: 29472357

17. Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units.

Besançon A, Brochard K, Dupic L, Gitiaux C, **Delville M**, Krid S, Quartier P, Saire E, Salomon R, Talbotec C, Bodemer C, Bader-Meunier B.

Rheumatology (Oxford). 2017 Oct 1; PMID: 28957568

18. Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target.

Kormann R, Jannot AS, Narjoz C, Ribeil JA, Manceau S, **Delville M**, Joste V, Prié D, Pouchot J, Thervet E, Courbebaisse M, Arlet JB.

Br J Haematol. 2017 Oct; PMID: 28699644

19. Arterio-venous fistula for automated red blood cells exchange in patients with sickle cell disease: Complications and outcomes.

Delville M, Manceau S, Ait Abdallah N, Stolba J, Awad S, Damy T, Gellen B, Sabbah L, Debbache K, Audard V, Beaumont JL, Arnaud C, Chantalat-Augier C, Driss F, Lefrère F, Cavazzana M, Franco G, Galacteros F, Ribeil JA, Gellen-Dautremere J.

Am J Hematol. 2017 Feb; PMID: 27813144

20. The costimulatory receptor B7-1 is not induced in injured podocytes.

Baye E, Gallazzini M, **Delville M**, Legendre C, Terzi F, Canaud G.

Kidney Int. 2016 Nov; PMID: 27528551

21. Pathogenesis of non-HLA antibodies in solid organ transplantation: Where do we stand?

Delville M, Charreau B, Rabant M, Legendre C, Anglicheau D.

Hum Immunol. 2016 Nov; PMID: 27237040

22. B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS.

Delville M, Baye E, Durrbach A, Audard V, Kofman T, Braun L, Olagne J, Nguyen C, Deschênes G, Moulin B, Delahousse M, Kesler-Roussey G, Beaudreuil S, Martinez F, Rabant M, Grimbert P, Gallazzini M, Terzi F, Legendre C, Canaud G.

J Am Soc Nephrol. 2016 Aug; PMID: 26701979

23. Recurrence of Focal and Segmental Glomerulosclerosis After Transplantation.

Canaud G, **Delville M**, Legendre C.

Transplantation. 2016 Feb; PMID: 26247557

24. Prevalence and predictors of early cardiovascular events after kidney transplantation: evaluation of pre-transplant cardiovascular work-up.

Delville M, Sabbah L, Girard D, Elie C, Manceau S, Piketty M, Martinez F, Méjean A, Legendre C, Sberro-Soussan R.

PLoS One. 2015 Jun 24; PMID: 26107641

25. Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection.

Rabant M, Amrouche L, Lebreton X, Aulagnon F, Benon A, Sauvaget V, Bonifay R, Morin L, Scemla A, **Delville M**, Martinez F, Timsit MO, Duong Van Huyen JP, Legendre C, Terzi F, Anglicheau D.

J Am Soc Nephrol. 2015 Nov; PMID: 25948873

26. Current aspects of acute humoral rejection.

Legendre C, Loupy A, Rabant M, Aubert O, Rabaté C, Delville M, Tinel C, Amrouche L, Martinez F, Snanoudj R,

Bererhi L, Scemla A, Sberro-Soussan R, Duong JP, Suberbielle C, Anglicheau D.

Nephrol Ther. 2014 Nov; PMID: 25440942

27. Endothelial cell antibodies associated with novel targets and increased rejection.

Jackson AM, Sigdel TK, **Delville M**, Hsieh SC, Dai H, Bagnasco S, Montgomery RA, Sarwal MM.

J Am Soc Nephrol. 2015 May; PMID: 25381426

28. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation.

Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, Burke GW, Bruneval P, Naesens M, Jackson A, Alachkar N, Canaud G, Legendre C, Anglicheau D, Reiser J, Sarwal MM.

Sci Transl Med. 2014 Oct 1; PMID: 25273097

29. Transpulmonary thermodilution measurements are not affected by continuous veno-venous hemofiltration at high blood pump flow.

Dufour N, **Delville M**, Teboul JL, Camous L, Favier du Noyer A, Richard C, Monnet X.

Intensive Care Med. 2012 Jul; PMID: 22543424

Projects

2021-2022 Design and implementation of 2 retrospective and one prospective clinical trials (as sponsor)

Starting in 2020 Leader of a Work Package in the RHU IRIS (PI. Pr Cavazzana)

Starting in 2016 Leader of a Work Package in the ERC Projet 693762 Gene For Cure (PI. Pr Cavazzana)

Co-investigator of the study GENHIV: Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced

with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma (ClinicalTrials.gov: NCT03593187)

Patients inclusion and follow-up in 8 commercial studies: REIN MARGINAL/ML21655 (Roche), CERTITEM / CRAD001AFR10 (Novartis), C10-001 (Alexion), ADHERE / PMR-EC-1212 (Astellas), PREFIGURE (Novartis), TRANSFORM (Novartis), SP005 (Sotio) and TKS-2014-001 (Therakos)

Study design, patients inclusion and follow-up, data monitoring and analysis in 10 academic protocols: RITUX – ERAH (Poitiers University Hospital), EVEROLD (Brest University Hospital), ASTRONEF (Nantes University Hospital), ADEQUATE (Tours University Hospital), TRIBUTE (Necker Hospital, Paris), DrepaMob (Necker Hospital, Paris), Cryostem (St Louis Hospital, Paris), Predictor 007 (St Louis Hospital, Paris), Drepa-FAV (Necker Hospital, Paris) and EP-PED (Necker Hospital, Paris)

DISTINCTION, GRANT and VALORIZATION

2019 Patents EP19305115.8, EP19305133.1

2018 Patent EP18306526.7

2016-2019 Inserm GRANT « Poste d'accueil »

2013 Grant from CENTAURE, Agence de la Biomédecine and Transplantex

2012 Award from the French Society of Nephrology

2010-2011 Assistance Publique-Hôpitaux de Paris research grant

Memberships

None

Other Relevant Information

None